# Multivac Evaluation Report

**Evaluation ID:** EVAL-20260402-195402
**Timestamp:** 2026-04-02T19:54:02.335437
**Category:** Analysis & Research
**Model Pool:** 10 analysis-optimized models

## Question

A pharmaceutical company reports: 'Our drug reduced hospitalization by 50% (p < 0.001). 2% of patients in the treatment group were hospitalized vs 4% in the control group.' (1) Calculate the absolute risk reduction and NNT (number needed to treat). (2) The trial had 200 patients. Is this enough for the claimed significance? (3) The control group received no treatment (not a placebo). Why is this problematic? (4) Side effects occurred in 8% of the treatment group. Should this drug be approved?

---

## Rankings

| Rank | Model | Score | Min | Max | Std Dev |
|------|-------|-------|-----|-----|---------|
| 1 | GPT-OSS-120B | 9.57 | 8.80 | 10.00 | 0.36 |
| 2 | Claude Sonnet 4.6 | 9.23 | 8.60 | 10.00 | 0.60 |
| 3 | Grok 4.20 | 9.22 | 8.45 | 10.00 | 0.53 |
| 4 | GPT-5.4 | 9.16 | 8.65 | 10.00 | 0.51 |
| 5 | Gemini 3 Flash Preview | 9.03 | 8.80 | 9.45 | 0.26 |
| 6 | Claude Opus 4.6 | 8.97 | 8.20 | 10.00 | 0.51 |
| 7 | DeepSeek V3 | 8.61 | 7.90 | 9.80 | 0.62 |
| 8 | MiMo-V2-Flash | 7.75 | 6.50 | 9.55 | 1.09 |
| 9 | Gemini 3.1 Pro | 7.51 | 6.45 | 8.60 | 0.79 |

---

## Meta Analysis

### Judge Strictness

| Rank | Judge | Avg Score Given |
|------|-------|-----------------|
| 1 | GPT-OSS-120B | 8.09 |
| 2 | GPT-5.4 | 8.26 |
| 3 | MiniMax M2.5 | 8.54 |
| 4 | Claude Opus 4.6 | 8.57 |
| 5 | Grok 4.20 | 8.71 |
| 6 | Claude Sonnet 4.6 | 8.73 |
| 7 | DeepSeek V3 | 8.99 |
| 8 | MiMo-V2-Flash | 9.14 |
| 9 | Gemini 3.1 Pro | 9.16 |
| 10 | Gemini 3 Flash Preview | 9.68 |

**Strictest Judge:** gpt_oss_120b
**Most Lenient Judge:** gemini_3_flash
**Total Judgments:** 100
**Valid Judgments:** 80

---

## Model Pool

Models selected for **Analysis & Research** evaluation:

1. **Gemini 3.1 Pro** (openrouter)
2. **Claude Opus 4.6** (openrouter)
3. **GPT-5.4** (openrouter)
4. **DeepSeek V3** (openrouter)
5. **MiMo-V2-Flash** (openrouter)
6. **Claude Sonnet 4.6** (openrouter)
7. **Grok 4.20** (openrouter)
8. **GPT-OSS-120B** (openrouter)
9. **Gemini 3 Flash Preview** (openrouter)
10. **MiniMax M2.5** (openrouter)

---

## Model Responses

### Gemini 3.1 Pro

**Generation Time:** 18713ms
**Tokens:** 2166

```
Here is the breakdown of the pharmaceutical company’s claims, analyzing the statistics, study design, and clinical relevance.

### 1. Calculate the Absolute Risk Reduction (ARR) and NNT
*   **Absolute Risk Reduction (ARR):** This is the simple difference in risk between the two groups.
    *   Control group risk = 4% (0.04)
    *   Treatment group risk = 2% (0.02)
    *   **ARR** = 4% - 2% = **2%** (or 0.02)
*   **Number Needed to Treat (NNT):** This tells you how many people you need to treat to prevent exactly one bad outcome (hospitalization).
    *   **NNT** = 1 / ARR = 1 / 0.02 = **50**
    *   *Meaning:* You must treat 50 patients with this drug to prevent 1 hospitalization.

### 2. Is a sample size of 200 enough for the claimed significance (p < 0.001)?
**No. In fact, the claimed p-value is mathematically impossible** with this sample size, strongly suggesting data error or fraud. 

Here is why: If there are 200 patients in the trial, we can assume roughly 100 are in the treatment group and 100 are in the control group.
*   Control group: 4% of 100 = **4 patients** hospitalized.
*   Treatment group: 2% of 100 = **2 patients** hospitalized.

A difference of just 2 events (4 hospitalizations vs. 2 hospitalizations) in a sample size of 200 is entirely likely to happen by random chance. If you run a standard statistical test (like Fisher's Exact Test or a Chi-Square test) on these numbers, the p-value would be roughly **0.40 to 0.68**, which is nowhere near the < 0.05 threshold for statistical significance, let alone < 0.001. To achieve a p-value of < 0.001 with 4% vs 2% event rates, the trial would need thousands of patients.

### 3. The control group received no treatment (not a placebo). Why is this problematic?
Failing to use a placebo introduces massive bias into the trial for several reasons:
*   **The Placebo Effect:** Patients who know they are receiving a new drug often experience
```

### Claude Opus 4.6

**Generation Time:** 38288ms
**Tokens:** 2179

```
# Critical Analysis of Pharmaceutical Trial Claims

## (1) Absolute Risk Reduction (ARR) and NNT

The company highlights the **relative risk reduction (RRR)** of 50%, which sounds dramatic. Let's examine the absolute numbers:

**Absolute Risk Reduction:**
$$ARR = \text{Control Event Rate} - \text{Treatment Event Rate} = 4\% - 2\% = 2\%$$
$$ARR = 0.02$$

**Number Needed to Treat:**
$$NNT = \frac{1}{ARR} = \frac{1}{0.02} = 50$$

### Interpretation
| Metric | Value | Impression |
|---|---|---|
| Relative Risk Reduction | 50% | Sounds revolutionary |
| Absolute Risk Reduction | 2% | Modest benefit |
| NNT | 50 | Must treat 50 patients for 1 to benefit |

> **Key insight:** The "50% reduction" is technically true but **deeply misleading**. This is a classic example of **relative risk framing bias** — presenting relative rather than absolute figures to inflate perceived efficacy. Moving from 4% to 2% is far less impressive than "50% reduction" suggests.

---

## (2) Statistical Power Analysis: Is n = 200 Sufficient?

### Sample Size Calculation for Two-Proportion Z-Test

Assuming equal groups: **n₁ = n₂ = 100**

For detecting a difference between p₁ = 0.04 and p₂ = 0.02:

**Using the standard formula:**
$$n = \frac{\left(Z_{\alpha/2}\sqrt{2\bar{p}(1-\bar{p})} + Z_{\beta}\sqrt{p_1(1-p_1) + p_2(1-p_2)}\right)^2}{(p_1 - p_2)^2}$$

Where:
- $\bar{p} = \frac{p_1 + p_2}{2} = 0.03$
- $Z_{\alpha/2} = 3.29$ (for p < 0.001, two-sided)
- $Z_{\beta} = 0.84$ (for 80% power)

**Numerator calculation:**
$$Z_{\alpha/2}\sqrt{2(0.03)(0.97)} = 3.29 \times \sqrt{0.0582} = 3.29 \times 0.2412 = 0.7936$$
$$Z_{\beta}\sqrt{0.04(0.96) + 0.02(0.98)} = 0.84 \times \sqrt{0.0384 + 0.0196} = 0.84 \times 0.2408 = 0.2023$$

$$n = \frac{(0.7936 + 0.2023)^2}{(0.02)^2} = \frac{(0.9959)^2}{0.0004} = \frac{0.9918}{0.0004} \approx 2{,}480 \text{ per group}$$

### Verdict

| Requirement | Available |
|---|---|
| **~2,480 per group** needed | **100 per group** available |
| **~4,960 total** needed | **200 total*...
```

### GPT-5.4

**Generation Time:** 19503ms
**Tokens:** 1327

```
Here’s a clear breakdown.

## 1) Absolute risk reduction and NNT

Hospitalization rates:

- **Treatment:** 2%
- **Control:** 4%

### Absolute Risk Reduction (ARR)
ARR = Control risk − Treatment risk

- **ARR = 4% − 2% = 2%**
- So the **absolute risk reduction is 2 percentage points**.

### Relative Risk Reduction (for context)
This is where the “50% reduction” comes from:

- (4% − 2%) / 4% = 50%

This sounds impressive, but the **absolute benefit is only 2%**.

### Number Needed to Treat (NNT)
NNT = 1 / ARR (using ARR as a proportion)

- ARR = 0.02
- NNT = 1 / 0.02 = **50**

So:

- **NNT = 50**

Meaning **50 patients must be treated to prevent 1 hospitalization**.

---

## 2) With 200 patients total, is this enough for p < 0.001?

Probably **no**.

If there were 200 patients total, that usually means about:

- **100 treatment**
- **100 control**

Then expected hospitalizations would be:

- Treatment: 2% of 100 = **2 hospitalized**
- Control: 4% of 100 = **4 hospitalized**

So the comparison is basically:

- **2/100 vs 4/100**

That is a very small difference in counts. It is **extremely unlikely** to produce **p < 0.001**.

### Why?
A p-value that small usually requires either:

- a **much larger effect**, or
- a **much larger sample size**

Here, the observed difference is only **2 events**.

A rough check:
- pooled event rate ≈ 3%
- standard error for difference ≈ 2.4%
- observed difference = 2%

So the z-score is less than 1, nowhere near what you’d need for p < 0.001.

### Conclusion
- **No, 200 total patients is not enough to credibly support p < 0.001 for 2% vs 4%.**
- The reported significance is **highly questionable** and may reflect:
  - a reporting error,
  - misuse of statistics,
  - or missing information.

---

## 3) Why is “no treatment” instead of placebo problematic?

This is a major trial design issue.

### Problems:

#### a) Lack of blinding
If the control group gets nothing, patients and clinicians may know who is receiving the drug.

This can bi...
```

### DeepSeek V3

**Generation Time:** 65276ms
**Tokens:** 949

```
Let's address each question systematically:

### (1) **Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT):**
- **Control group risk (CER):** 4% (0.04)  
- **Treatment group risk (EER):** 2% (0.02)  
- **Absolute Risk Reduction (ARR) = CER − EER = 0.04 − 0.02 = 0.02 (2%)**  
- **Number Needed to Treat (NNT) = 1 / ARR = 1 / 0.02 = 50**  

**Answer:**  
- **ARR = 2%**  
- **NNT = 50**  

---

### (2) **Is a trial with 200 patients sufficient for the claimed significance (p < 0.001)?**
To assess whether the sample size supports the p-value, we can perform a **two-proportion z-test**:

- **Treatment group:** 2% hospitalized → 2 out of 100  
- **Control group:** 4% hospitalized → 4 out of 100  

**Pooled proportion (p̄) = (2 + 4) / (100 + 100) = 0.03**  
**Standard error (SE) = √[p̄(1−p̄)(1/n₁ + 1/n₂)] ≈ 0.024**  
**Z-score = (0.02 − 0.04) / SE ≈ −0.833**  

This yields a **p-value ≈ 0.20**, which is **not significant (p < 0.001 is not achieved)**.  

**Possible explanations:**  
- The reported p-value may derive from a **different statistical test** (e.g., survival analysis).  
- The trial might have **more patients** (if the 200 is per group, not total).  

**Answer:**  
No, 200 patients are insufficient for p < 0.001 with these proportions. Either the sample size is larger or another statistical method was used.  

---

### (3) **Why is giving the control group no treatment (not a placebo) problematic?**  
- **Placebo effect:** Without blinding, patients in the control group may behave differently (e.g., seek other treatments), biasing results.  
- **Observer bias:** Investigators might unconsciously favor the treatment group if they know who is receiving the drug.  
- **Ethical concerns:** If standard treatment exists, withholding all treatment may be unethical.  

**Answer:**  
Lack of a placebo introduces bias (placebo effect, observer bias) and may raise ethical concerns if standard care exists.  

---

### (4) **Should the drug be approved given 8% sid...
```

### MiMo-V2-Flash

**Generation Time:** 44241ms
**Tokens:** 1063

```
Here are the answers to your questions based on the data provided.

### (1) Absolute Risk Reduction (ARR) and NNT

*   **Absolute Risk Reduction (ARR):** This is the difference between the control event rate and the treatment event rate.
    *   Control Event Rate (CER) = 4%
    *   Treatment Event Rate (TER) = 2%
    *   **ARR = 4% - 2% = 2% (or 0.02)**
*   **Number Needed to Treat (NNT):** This is the inverse of the ARR.
    *   Formula: $1 / ARR$
    *   Calculation: $1 / 0.02 = 50$
    *   **NNT = 50**

**Interpretation:** For every 50 patients treated with this drug, one hospitalization is prevented compared to no treatment.

***

### (2) Is 200 patients enough for the claimed significance?

**Yes, the sample size appears sufficient.**

Although the sample size is small ($N=200$), the effect size is large enough to be statistically significant with $p < 0.001$.

Here is the breakdown:
*   **Total patients:** 200
*   **Control group (approx. 100):** 4% hospitalized = 4 people.
*   **Treatment group (approx. 100):** 2% hospitalized = 2 people.

While having only 6 "events" (hospitalizations) total is very low, the statistical test (likely a Chi-square or Fisher’s exact test) calculates that the probability of seeing this result by random chance is less than 0.001. The extremely low $p$-value indicates that the result is statistically robust despite the small sample size.

***

### (3) Why is it problematic that the control group received no treatment (not a placebo)?

Using an "untreated" control group rather than a placebo introduces **Performance Bias** and **Expectation Bias**.

1.  **Lack of Blinding:** In a placebo-controlled trial, neither the patient nor the doctor knows who is getting the drug. If the control group gets nothing, the doctors and patients know exactly who is receiving the active drug.
2.  **The Placebo Effect:** Patients who know they are receiving treatment often report better outcomes (or, in this case, might be treated more aggressively ...
```

### Claude Sonnet 4.6

**Generation Time:** 32444ms
**Tokens:** 1900

```
# Critical Analysis of Pharmaceutical Trial Claims

## (1) Absolute Risk Reduction and NNT

### Calculations

**Relative Risk Reduction (what they reported):**
$$RRR = \frac{4\% - 2\%}{4\%} = \frac{2\%}{4\%} = 50\%$$

**Absolute Risk Reduction (what matters):**
$$ARR = 4\% - 2\% = \mathbf{2\%}$$

**Number Needed to Treat:**
$$NNT = \frac{1}{ARR} = \frac{1}{0.02} = \mathbf{50 \text{ patients}}$$

### Why This Gap Is Critical

| Metric | Value | Impression Given |
|--------|-------|-----------------|
| Relative Risk Reduction | 50% | Dramatic benefit |
| Absolute Risk Reduction | 2% | Modest benefit |
| NNT | 50 | 49 patients treated with no benefit |

> **The company used RRR specifically because it sounds more impressive — this is a known statistical manipulation tactic called "relative risk framing"**

---

## (2) Sample Size and Statistical Power Analysis

### What the Numbers Actually Show

With 200 patients split into two groups:
- **Treatment group:** ~100 patients → 2 hospitalized
- **Control group:** ~100 patients → 4 hospitalized
- **Difference:** literally **2 patients**

### Formal Power Calculation

For detecting a 2% absolute difference with:
- α = 0.05 (p < 0.001 is even stricter)
- Power = 80%
- Baseline rate = 4%

$$n = \frac{(Z_{\alpha/2} + Z_{\beta})^2 \cdot [p_1(1-p_1) + p_2(1-p_2)]}{(p_1 - p_2)^2}$$

$$n \approx \frac{(3.09 + 0.84)^2 \cdot [0.04(0.96) + 0.02(0.98)]}{(0.02)^2} \approx \mathbf{1,700+ \text{ patients per group}}$$

### The p < 0.001 Claim Is Almost Certainly Wrong

```
Fisher's Exact Test with these numbers:
|              | Hospitalized | Not Hospitalized |
|--------------|-------------|-----------------|
| Treatment    |      2      |       98        |
| Control      |      4      |       96        |

Actual p-value ≈ 0.41 — NOT significant
```

**Conclusion:** Either the p-value is fabricated, miscalculated, or refers to a *different* outcome than reported. **200 patients cannot generate p < 0.001 for a 2% absolute difference.**

...
```

### Grok 4.20

**Generation Time:** 4323ms
**Tokens:** 1046

```
**1. Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT)**

- Control Event Rate (CER) = 4% = 0.04  
- Experimental Event Rate (EER) = 2% = 0.02  

**Absolute Risk Reduction (ARR)** = CER − EER = 0.04 − 0.02 = **0.02 (2%)**

**Number Needed to Treat (NNT)** = 1 / ARR = 1 / 0.02 = **50**

Interpretation: You need to treat 50 patients with the drug to prevent one additional hospitalization compared to no treatment. The ARR of 2% is modest despite the impressive-sounding “50% reduction.”

**2. Is n = 200 enough for p < 0.001?**

No, it is not plausible.

With 200 patients total, assume 1:1 randomization → ~100 per arm.

Expected events:  
- Treatment: 2% of 100 = **2 hospitalizations**  
- Control: 4% of 100 = **4 hospitalizations**

This is a 2×2 contingency table with only 6 total events. Using Fisher’s exact test (the appropriate test here), the p-value for 2 vs 4 events is approximately **p = 0.68** — nowhere near p < 0.001.

Even with a chi-square test (inappropriate with such small counts), you get p ≈ 0.41.

**Conclusion**: The reported p < 0.001 is statistically impossible with only 200 patients and these event rates. The company is either:
- grossly miscalculating statistics,
- using a completely different (and likely inappropriate) endpoint or analysis, or
- fabricating the p-value.

This is a major red flag.

**3. Why is “no treatment” in the control group problematic?**

This is a major design flaw for several reasons:

- **Lack of blinding**: Both patients and investigators know who is receiving the active drug. This introduces strong placebo effects, performance bias, and detection bias (e.g., doctors may hospitalize control patients more readily).
- **Nocebo effect** in the control group: Patients who know they’re getting nothing may report worse symptoms or seek hospitalization more.
- **Cannot isolate the pharmacological effect**: Any difference could be due to expectation, extra attention, or behavioral changes rather than the drug itself.
...
```

### GPT-OSS-120B

**Generation Time:** 15947ms
**Tokens:** 2065

```
**(1) Absolute risk reduction (ARR) and number‑needed‑to‑treat (NNT)**  

|                     | Hospitalised | Not hospitalised | Total |
|---------------------|--------------|------------------|-------|
| **Treatment**       | 2 % (≈ 2)    | 98 % (≈ 98)       | 100 |
| **Control**         | 4 % (≈ 4)    | 96 % (≈ 96)       | 100 |

* **Absolute risk reduction**  
\[
\text{ARR}= \text{Risk}_{\text{control}}-\text{Risk}_{\text{treatment}}
          = 0.04-0.02 = 0.02 \;(\text{or }2\%).
\]

* **Number‑needed‑to‑treat**  
\[
\text{NNT}= \frac{1}{\text{ARR}} = \frac{1}{0.02}=50.
\]  

Interpretation: you would have to treat **≈ 50 patients** with the drug to prevent **one additional hospitalisation**.

---

**(2) Is a total of 200 patients enough to justify the claim “p < 0.001”?**  

Assuming equal randomisation (100 per arm) the observed counts are:

* Treatment: 2/100 hospitalised  
* Control: 4/100 hospitalised  

A quick two‑sample proportion test:

\[
\hat p_1 =0.02,\qquad \hat p_2 =0.04,\qquad
SE = \sqrt{\frac{p_1(1-p_1)}{n_1}+\frac{p_2(1-p_2)}{n_2}}
     \approx \sqrt{\frac{0.0196}{100}+\frac{0.0384}{100}}
     =0.0241.
\]

\[
Z = \frac{\hat p_1-\hat p_2}{SE}= \frac{-0.02}{0.0241}\approx -0.83,
\]
two‑sided *p* ≈ 0.40.  

A Fisher‑exact test on the 2 × 2 table (2 vs 4 events) gives *p* ≈ 0.68.  

**Conclusion:** With only 200 participants the data are **far from statistically significant**; a *p*‑value of <0.001 is impossible with these event numbers. The study is severely under‑powered for the modest absolute difference observed.

---

**(3) Why is a “no‑treatment” control (instead of a placebo) problematic?**  

| Issue | Explanation |
|-------|-------------|
| **Lack of blinding** | Patients and investigators know who receives the active drug. This can influence reporting of outcomes (e.g., patients may be more likely to seek care, investigators may be more vigilant) → expectation/placebo effects. |
| **Differential co‑interventions** | Knowing they are “un...
```

### Gemini 3 Flash Preview

**Generation Time:** 6763ms
**Tokens:** 866

```
Here are the calculations and analysis based on the data provided:

### 1. Calculations
*   **Absolute Risk Reduction (ARR):** This is the arithmetic difference between the control group risk and the treatment group risk.
    *   $4\% - 2\% = \mathbf{2\%}$ (or 0.02).
*   **Number Needed to Treat (NNT):** This represents how many patients must be treated to prevent one additional negative outcome (hospitalization). It is the inverse of the ARR.
    *   $1 / 0.02 = \mathbf{50}$.
    *   *Interpretation:* You need to treat 50 people with this drug to prevent one hospitalization.

### 2. Is the trial size enough for the claimed significance?
**No.** There is a major discrepancy between the reported p-value ($p < 0.001$) and the sample size ($n=200$).
*   In a trial of 200 patients (assuming 100 per group):
    *   Control group (4%): 4 hospitalizations.
    *   Treatment group (2%): 2 hospitalizations.
*   A difference between 4 events and 2 events in a sample of 200 is **not statistically significant.** Using a standard Fisher’s Exact Test or Chi-square test, the p-value would be approximately **0.68**, which is far above the standard threshold of 0.05. 
*   To achieve $p < 0.001$ with these specific percentages (2% vs 4%), the trial would likely need **thousands of patients**, not 200.

### 3. Why is the lack of a placebo problematic?
Using "no treatment" instead of a placebo introduces **bias** that can invalidate the results:
*   **The Placebo Effect:** Patients who know they are receiving a new drug may report feeling better or seek medical help less urgently due to psychological expectations.
*   **Observer Bias:** If the trial was not "double-blind," doctors might subconsciously treat the "no treatment" group differently or be more likely to hospitalize them because they know they aren't protected by the drug.
*   **Confounding Variables:** Without a placebo, you cannot determine if the 2% reduction was caused by the chemical properties of the drug or simply the ...
```

### MiniMax M2.5

**Generation Time:** 81945ms
**Tokens:** 2203

```

```

---

*Generated by The Multivac V5*
*https://themultivac.com*